![](https://capedge.com/proxy/CORRESP/0001144204-11-000365/logo.jpg)
January 4, 2011
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: | Jeffrey Riedler, Assistant Director |
John Krug, Senior Counsel
Via: | EDGAR Submission |
Re: | XTL Biopharmaceuticals Ltd. |
Form 20-F filed June 30, 2010
File No. 000-51310
Ladies and Gentlemen:
Today, XTL Biopharmaceuticals Ltd. (the “Company”) received by United States Postal Service a letter from the Securities and Exchange Commission (the “Commission”), dated December 6, 2010, which requests comments on the Company’s Form 20-F filed June 30, 2010.
Pursuant to a telephone conversation held today between myself and Mr. Jeffrey Riedler, the Company and the Commission have agreed that the date of response to the above-referenced letter will be delayed until January 18, 2011 due to the late receipt of the letter.
Thank you for your assistance.
XTL Biopharmaceuticals Ltd. | |||||
By: | /s/ David Grossman | ||||
David Grossman | |||||
Chief Executive Officer |
XTL Biopharmaceuticals Ltd. 85 Medinat Hayehudim St., Herzliya Pituach 46766, Israel Tel: +972-9-955-7080 Fax: +972-9-951-9727